Appendix 4E & Annual Report to 30 June 2026
Emvision Medical Devices Ltd
Key points
- FY26 revenue increased by 57% to $8.85M
- Loss after tax decreased by 15% to $8.32M
- FDA De Novo submission for emu¢ underway
- First Responder program progresses with positive feedback
- Well-funded with $17.1M in cash and $4.6M in non-dilutive grants
Full summary
Emvision Medical Devices Ltd. released its FY26 Annual Report, highlighting a 57% increase in revenue to $8.85M, driven by higher grant income and R&D Tax Incentive rebates. The loss after tax decreased by 15% to $8.32M. The company is making significant progress with its emu¢ bedside scanner, with the pivotal trial enrolling strongly at leading stroke centers in the US and Australia. The First Responder program also advanced, with positive feedback from field studies conducted in collaboration with the Royal Flying Doctor Service, Ambulance Victoria, and the Australian Stroke Alliance. The company ended FY26 with $17.1M in cash and $4.6M in non-dilutive grants, positioning it well for future growth.
Outlook
Emvision is focused on completing the emu¢ pivotal trial, submitting its FDA De Novo application, and advancing the First Responder program towards commercialization.